In:
Pharmacogenomics, Future Medicine Ltd, Vol. 20, No. 7 ( 2019-05), p. 483-492
Abstract:
Aim: The aim of this study was to determine the impact of genetic and nongenetic factors on treatment outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary intervention and stent implantation. Materials & methods: Patients (n = 628) used clopidogrel or ticagrelor for at least 1 week before platelet aggregation test. Results: Multivariate binary regression analysis demonstrated that aspirin use and CYP4F2 T allele significantly increased odds for bleeding in clopidogrel users (OR: 2.488, 95% CI: 1.452–4.265; p = 0.001 and OR: 1.573, 95% CI: 1.066–2.320; respectively; p = 0.022). CYP4F2 T allele significantly increased odds for bleeding in ticagrelor users (OR: 8.270, 95% CI: 3.917–17.462; p 〈 0.001). Conclusion: Aspirin use and CYP4F2 T allele were significantly associated with bleeding during dual antiplatelet therapy.
Type of Medium:
Online Resource
ISSN:
1462-2416
,
1744-8042
DOI:
10.2217/pgs-2018-0178
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2019
SSG:
15,3
Bookmarklink